A number of firms have modified their ratings and price targets on shares of IQVIA (NYSE: IQV) recently:
- 10/29/2026 – IQVIA had its price target raised by TD Cowen from $288.00 to $307.00. They now have a “buy” rating on the stock.
- 10/28/2026 – IQVIA was downgraded by Weiss Ratings from “hold (c+)” to “sell (d+)”.
- 10/28/2026 – IQVIA had its price target raised by Truist Financial from $329.00 to $346.00. They now have a “buy” rating on the stock.
- 10/28/2026 – IQVIA had its price target raised by JPMorgan Chase & Co. from $295.00 to $325.00. They now have an “overweight” rating on the stock.
- 10/27/2026 – IQVIA had its price target raised by Robert W. Baird from $324.00 to $328.00. They now have an “outperform” rating on the stock.
- 10/19/2026 – IQVIA had its price target raised by BMO Capital Markets from $270.00 to $305.00.
- 10/15/2026 – IQVIA had its price target lowered by Deutsche Bank Aktiengesellschaft from $191.00 to $179.00.
- 10/14/2026 – IQVIA had its price target raised by JPMorgan Chase & Co. from $285.00 to $295.00.
- 10/14/2026 – IQVIA had its price target raised by Stifel Nicolaus from $276.00 to $303.00. They now have a “buy” rating on the stock.
- 10/8/2026 – IQVIA had its price target raised by Leerink Partners from $280.00 to $310.00. They now have an “outperform” rating on the stock.
- 10/7/2026 – IQVIA had its price target raised by Mizuho from $275.00 to $300.00. They now have an “outperform” rating on the stock.
- 10/7/2026 – IQVIA had its price target raised by Barclays from $275.00 to $300.00. They now have an “overweight” rating on the stock.
- 10/6/2026 – IQVIA had its price target raised by Evercore from $275.00 to $290.00. They now have an “outperform” rating on the stock.
- 9/30/2026 – IQVIA is now covered by UBS Group. They set a “buy” rating and a $345.00 price target on the stock.
- 9/30/2026 – IQVIA was upgraded by UBS Group from “buy” to “strong-buy”. They now have a $345.00 price target on the stock, up from $240.00.
- 9/29/2026 – IQVIA had its price target raised by Robert W. Baird from $287.00 to $324.00. They now have an “outperform” rating on the stock.
- 9/29/2026 – IQVIA had its price target raised by Royal Bank Of Canada from $247.00 to $319.00. They now have an “outperform” rating on the stock.
- 9/28/2026 – IQVIA had its “buy” rating reaffirmed by Truist Financial. They now have a $329.00 price target on the stock, up from $300.00.
- 9/24/2026 – IQVIA was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
- 9/17/2026 – IQVIA had its price target raised by Morgan Stanley from $240.00 to $270.00. They now have an “equal weight” rating on the stock.
- 9/12/2026 – IQVIA was upgraded by Wall Street Zen from “hold” to “buy”.
IQVIA Stock Performance
Shares of IQVIA stock traded up $3.31 during trading on Wednesday, hitting $265.90. 408,297 shares of the stock were exchanged, compared to its average volume of 1,681,945. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $284.50. The stock’s fifty day moving average is $266.22 and its 200 day moving average is $210.59. The stock has a market cap of $43.82 billion, a PE ratio of 32.31, a P/E/G ratio of 2.30 and a beta of 1.16.
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period last year, the firm posted $3.00 EPS. IQVIA’s quarterly revenue was up 8.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current year.
Insider Transactions at IQVIA
In related news, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is owned by company insiders.
IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.
Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.
Read More
- Five stocks we like better than IQVIA
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
- Bloom Energy: The Off-Grid Answer to AI’s Power Drain
- Space Race 2.0: Intuitive Machines Secures Another NASA Contract
Receive News & Ratings for IQVIA Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.
